Vilazodone: Difference between revisions
From Pharmacopedia
More actions
| [checked revision] | [checked revision] |
Terminology sweep: drug/medication → medicine |
MDElliottMD (talk | contribs) Tier 2 taxonomy consolidation: remove Category:Serotonin Reuptake Inhibitors |
||
| (One intermediate revision by the same user not shown) | |||
| Line 14: | Line 14: | ||
| pregnancy = Limited data; weigh benefits/risks | | pregnancy = Limited data; weigh benefits/risks | ||
| legal = Rx | | legal = Rx | ||
| intro = '''Vilazodone''' (brand name Viibryd) is a serotonin partial agonist reuptake inhibitor (SPARI) FDA-approved in 2011 for major depressive disorder. Combines SERT inhibition with 5HT1A receptor partial agonism | | intro = '''Vilazodone''' (brand name Viibryd) is a serotonin partial agonist reuptake inhibitor (SPARI) FDA-approved in 2011 for major depressive disorder. Combines SERT inhibition with 5HT1A receptor partial agonism, similar in spirit to buspirone-augmented SSRI therapy, but in a single molecule. Stahl positions SPARIs as a mechanistic refinement of SSRIs intended to accelerate the typical 4-6 week onset and improve tolerability via 5HT1A modulation. | ||
In practice, head-to-head trials have not consistently shown superiority over generic SSRIs. The medicine carries the typical SSRI side effect profile though sexual dysfunction may be somewhat reduced. Must be taken with food (substantial bioavailability difference). | In practice, head-to-head trials have not consistently shown superiority over generic SSRIs. The medicine carries the typical SSRI side effect profile though sexual dysfunction may be somewhat reduced. Must be taken with food (substantial bioavailability difference). | ||
| Line 26: | Line 26: | ||
[[Category:Selective Serotonin Reuptake Inhibitors (SSRIs)]] | [[Category:Selective Serotonin Reuptake Inhibitors (SSRIs)]] | ||
[[Category:Serotonin Partial Agonist Reuptake Inhibitors (SPARIs)]] | [[Category:Serotonin Partial Agonist Reuptake Inhibitors (SPARIs)]] | ||